Thalidomide-O-amido-C4-NH2 (Cereblon Ligand-Linker Conjugates 6) is a synthesized ligand-linker conjugate that combines a Thalidomide-based cereblon ligand with a linker. It functions as an E3 ligase ligand-linker conjugate and finds applications in the synthesis of PROTACs[1].
Lenalidomide-C4-NH2 hydrochloride is a Cereblon ligand derived from Lenalidomide. It serves as a recruiting agent for the CRBN protein. The compound, known as PROTAC (Compound 24), can be formed by linking Lenalidomide-C4-NH2 hydrochloride to the ligand for the protein. It exhibits inhibitory effects with IC50s of 0.98 nM and 13.7 nM against the growth of RS4;11 and MOLM-13 acute leukemia cell lines, respectively[1].
Pomalidomide-amido-C4-amido-PEG2-C2-NH-Boc is a novel synthesized conjugate compound functioning as an E3 ligase ligand-linker in PROTAC technology. This compound incorporates a Pomalidomide-derived cereblon ligand, which binds selectively to the E3 ligase cereblon, and a 2-unit PEG linker, which provides stability and flexibility to the conjugate.
Pomalidomide-amido-C4-amido-C6-NH-Boc, a synthesized conjugate, is a ligand-linker incorporating the cereblon ligand based on Pomalidomide and a PROTAC technology linker.
PROTAC CARM1/IKZF3 degrader-1 (Compound 074) 抑制CARM1并减少其底物BAF155的甲基化。它是通过CRBN依赖途径降解IKZF 1/3的PROTAC降解剂,抑制MYC蛋白表达,以减缓多发性骨髓瘤细胞的增殖,并诱导H929细胞凋亡 (apoptosis)。此外,该化合物能够克服对免疫调节药物(IMiD,如泊马度胺)的耐药性,适用于癌症和免疫学研究。(Pink: ligand for target protein CARM1/IKZF3 ligand 1; Active form of target protein ligand: EZM 2302; Black: linker; Blue: ligand for E3 ligase Cereblon Thalidomide 4-fluoride)